Merck claims hepatitis C patent win
Gil C / Shutterstock.com
A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck, Gilead, hepatitis C, patent infringement, damages, patent, Harvoni, Sovaldi, US District Court for the Northern District of California